Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to purchase up to 750,000 additional shares of common stock at the public offering price, less the underwriting discount.
Citigroup, J.P. Morgan and Cowen are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
A registration statement relating to the offering has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.
This offering is being made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained by contacting: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (631) 274-2806.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Apellis
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the Securities and Exchange Commission, Apellis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19, 2018, and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact: Alex Kane [email protected] 212.301.7218 (office) 929.400.2691 (mobile) Media Contact: Tully Nicholas [email protected] 617.482.0042 (office) 860.490.0218 (mobile)
